Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$1.75
+6.7%
$1.59
$1.20
$6.75
$99.19M2.631.48 million shs1.38 million shs
Compugen Ltd. stock logo
CGEN
Compugen
$1.32
+4.8%
$1.45
$1.13
$2.66
$117.79M2.61387,861 shs232,144 shs
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$2.75
+3.4%
$3.11
$2.01
$5.64
$182.95M1.811.12 million shs797,384 shs
SPK Acquisition Corp. stock logo
SPK
SPK Acquisition
$10.30
$10.22
$9.84
$10.68
$67.94M-0.0112,839 shs33,515 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
+6.71%+4.79%+25.90%-19.72%-71.36%
Compugen Ltd. stock logo
CGEN
Compugen
+4.76%-3.65%+4.76%-38.60%-34.33%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
+3.38%+2.61%+11.34%-33.89%-18.88%
SPK Acquisition Corp. stock logo
SPK
SPK Acquisition
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
3.4522 of 5 stars
3.54.00.00.02.82.51.3
Compugen Ltd. stock logo
CGEN
Compugen
1.865 of 5 stars
3.54.00.00.02.00.00.0
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
1.393 of 5 stars
3.50.00.00.03.00.00.6
SPK Acquisition Corp. stock logo
SPK
SPK Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
3.00
Buy$14.60734.29% Upside
Compugen Ltd. stock logo
CGEN
Compugen
3.00
Buy$4.00203.03% Upside
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
3.00
Buy$12.00336.36% Upside
SPK Acquisition Corp. stock logo
SPK
SPK Acquisition
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SPK, BDTX, CGEN, and CRDF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$17.00 ➝ $18.00
3/19/2025
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
3/18/2025
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$11.00 ➝ $12.00
3/7/2025
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
3/7/2025
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$16.00 ➝ $11.00
2/28/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $17.00
(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/AN/AN/AN/A$2.26 per shareN/A
Compugen Ltd. stock logo
CGEN
Compugen
$27.86M4.23N/AN/A$0.73 per share1.81
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$683K267.86N/AN/A$1.56 per share1.76
SPK Acquisition Corp. stock logo
SPK
SPK Acquisition
N/AN/AN/AN/A($0.19) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-$82.44M-$1.27N/AN/AN/AN/A-68.08%-49.65%N/A
Compugen Ltd. stock logo
CGEN
Compugen
-$18.75M-$0.1666.00N/AN/A2.67%2.62%1.36%5/19/2025 (Estimated)
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$41.44M-$0.94N/AN/AN/A-6,238.17%-73.97%-60.40%N/A
SPK Acquisition Corp. stock logo
SPK
SPK Acquisition
-$420KN/A0.00N/AN/AN/A-1.95%N/A

Latest SPK, BDTX, CGEN, and CRDF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/19/2025Q1 2025
Compugen Ltd. stock logo
CGEN
Compugen
-$0.06N/AN/AN/A$3.70 millionN/A
5/8/2025Q1 2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 million
3/6/2025Q4 2024
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-$0.31-$0.28+$0.03-$0.28N/AN/A
3/4/2025Q4 2024
Compugen Ltd. stock logo
CGEN
Compugen
$0.07-$0.07-$0.14-$0.07$17.47 million$1.47 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/AN/AN/AN/AN/A
Compugen Ltd. stock logo
CGEN
Compugen
N/AN/AN/AN/AN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
SPK Acquisition Corp. stock logo
SPK
SPK Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/A
5.55
5.55
Compugen Ltd. stock logo
CGEN
Compugen
N/A
4.14
4.14
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
4.74
4.74
SPK Acquisition Corp. stock logo
SPK
SPK Acquisition
N/A
4.64
4.64

Institutional Ownership

CompanyInstitutional Ownership
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
95.47%
Compugen Ltd. stock logo
CGEN
Compugen
12.22%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
SPK Acquisition Corp. stock logo
SPK
SPK Acquisition
19.64%

Insider Ownership

CompanyInsider Ownership
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
8.87%
Compugen Ltd. stock logo
CGEN
Compugen
9.50%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
7.80%
SPK Acquisition Corp. stock logo
SPK
SPK Acquisition
22.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
9056.68 million51.57 millionOptionable
Compugen Ltd. stock logo
CGEN
Compugen
7089.24 million80.76 millionOptionable
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2066.53 million47.15 millionOptionable
SPK Acquisition Corp. stock logo
SPK
SPK Acquisition
2,0216.60 million5.12 millionNot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Black Diamond Therapeutics stock logo

Black Diamond Therapeutics NASDAQ:BDTX

$1.75 +0.11 (+6.71%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$1.88 +0.13 (+7.14%)
As of 07:56 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Compugen stock logo

Compugen NASDAQ:CGEN

$1.32 +0.06 (+4.76%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$1.31 -0.01 (-1.06%)
As of 07:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$2.75 +0.09 (+3.38%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$2.80 +0.06 (+2.00%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

SPK Acquisition stock logo

SPK Acquisition NASDAQ:SPK

SPK Acquisition Corp. intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on operating businesses in the telecommunications, media, and technology sectors in Asia. The company was incorporated in 2020 and is based in Shanghai, China.